01 μm and 13.18, respectively. PAMPA assays for all compounds were carried out in order to evaluate the capacity of the compounds to cross the blood-brain barrier. Moreover, the most potent MAO-B inhibitor, TB5, was found to be nontoxic at 5 and 25 μm, with 95.75 and 84.59 % viability among cells, respectively. Molecular docking simulations were carried out to understand the crucial interactions responsible
合成了一系列(2E)-1-(5-
溴噻吩-2-基)-3-(对位取代苯基)丙-2-烯-1-酮(TB1-TB11),并测试了其对人的抑制活性单胺氧化酶(hMAO)。除了(2E)-1-(5-
溴噻吩-2-基)-3-(4-
硝基苯基)丙-2-烯-1-酮((2E)-1-(5-
溴噻吩-2-基)-3-(4-
硝基苯基)丙-2-烯-1-酮( TB7)和(2E)-1-(5-
溴噻吩-2-基)-3-(4-
氯苯基)丙-2-烯-1-酮(TB8),它们是hMAO-A的选择性
抑制剂。最有效的化合物(2E)-1-(5-
溴噻吩-2-基)-3- [4-(二甲基
氨基)苯基]丙-2-烯-1-酮(TB5)显示出最佳的抑制活性和对hMAO-B的选择性更高,Ki和SI值分别为0.11±0.01μm和13.18。为了评估化合物穿过血脑屏障的能力,对所有化合物进行了P
AMPA分析。而且,发现最有效的MAO-B
抑制剂TB5在5和25μm无毒,在细胞中的存活率分别为95